Jundishapur Journal of Microbiology

Published by: Kowsar

Determination of Changes in the Expression of MIR-212 and EGFR Genes in Clinical Samples from Areas Infected with Trichophyton rubrum Compared with Non-Infected Areas

Maryam Esfidani 1 , Seyed Amin Ayatollahi Mousavi 1 , * , Seyed Amir Yazdanparast 2 , Mohammad Shafiee 3 and Monireh Mohsenzadegan 4
Authors Information
1 Department of Parasitology and Mycology, Faculty of Medicine, Kerman University of Medical Sciences and Health Services, Kerman, Iran
2 Department of Laboratory Sciences, Faculty of Paramedicine, Iran University of Medical Sciences and Health Services, Tehran, Iran
3 Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
4 Department of Laboratory Sciences, Faculty of Paramedicine, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: 11 (11); e62885
  • Published Online: October 17, 2018
  • Article Type: Research Article
  • Received: October 15, 2017
  • Revised: September 27, 2018
  • Accepted: September 29, 2018
  • DOI: 10.5812/jjm.62885

To Cite: Esfidani M, Ayatollahi Mousavi S A, Yazdanparast S A, Shafiee M , Mohsenzadegan M. Determination of Changes in the Expression of MIR-212 and EGFR Genes in Clinical Samples from Areas Infected with Trichophyton rubrum Compared with Non-Infected Areas, Jundishapur J Microbiol. Online ahead of Print ; 11(11):e62885. doi: 10.5812/jjm.62885.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51 Suppl 4:2-15. doi: 10.1111/j.1439-0507.2008.01606.x. [PubMed: 18783559].
  • 2. Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166(5-6):335-52. doi: 10.1007/s11046-008-9100-9. [PubMed: 18478365].
  • 3. Brasch J. Pathogenesis of tinea. J Dtsch Dermatol Ges. 2010;8(10):780-6. doi: 10.1111/j.1610-0387.2010.07481.x. [PubMed: 20678152].
  • 4. Gruby D. [Memory about a vegetation that is the true ringworm]. CR Acad Sci. 1841;13:72-5. French.
  • 5. Seeliger HP. The discovery of Achorion schoenleinii. Facts and stories (Johann Lucas Schoenlein and Robert Remak). Mykosen. 1985;28(4):161-82. doi: 10.1111/j.1439-0507.1985.tb02110.x. [PubMed: 3889638].
  • 6. Castellani A. Observations on a new species of epidermo-phyton found in tinea cruris. Brit J Dermatol. 1910;22(5):147-50. doi: 10.1111/j.1365-2133.1910.tb16618.x.
  • 7. Rippon JW. The changing epidemiology and emerging patterns of dermatophyte species. Curr Top Med Mycol. 1985;1:208-34. doi: 10.1007/978-1-4613-9547-8_8. [PubMed: 3916767].
  • 8. Sabouraud RJA. [Les Teignes. Maladies du cuir chevelu. 3. Les Maladies cryptogamiques]. Paris: Masson et Cie; 1910. French.
  • 9. de Hoog GS, Dukik K, Monod M, Packeu A, Stubbe D, Hendrickx M, et al. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. Mycopathologia. 2017;182(1-2):5-31. doi: 10.1007/s11046-016-0073-9. [PubMed: 27783317]. [PubMed Central: PMC5283515].
  • 10. Amir Y. [Medical mycology cutaneous mycoses (dermatophytosis)]. 1. Iran University of Medical Sciences; 2008. 87 p. Persian.
  • 11. Maraki S. Epidemiology of dermatophytoses in Crete, Greece between 2004 and 2010. G Ital Dermatol Venereol. 2012;147(3):315-9. [PubMed: 22648332].
  • 12. Williams W; Fellow of the Royal College of Veterinary Surgeons. The principles and practice of veterinary surgery newed. 2nd ed. America, New York: Cornell University Library, WR Jenkins; 1894.
  • 13. Gibas CF, Sigler L, Summerbell RC, Hofstader SL, Gupta AK. Arachnomyces kanei (anamorph Onychocola kanei) sp. nov., from human nails. Med Mycol. 2002;40(6):573-80. doi: 10.1080/mmy.40.6.573.580. [PubMed: 12521121].
  • 14. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8(2):240-59. [PubMed: 7621400]. [PubMed Central: PMC172857].
  • 15. Harder J, Schroder JM, Glaser R. The skin surface as antimicrobial barrier: Present concepts and future outlooks. Exp Dermatol. 2013;22(1):1-5. doi: 10.1111/exd.12046. [PubMed: 23088757].
  • 16. Harder J, Schroder JM. Antimicrobial peptides in human skin. In: Kabelitz D, Schroder JM, editors. Mechanisms of epithelial defense. 86. Karger Medical and Scientific Publishers; 2005. p. 22-41.
  • 17. Glaser R, Becker K, von Eiff C, Meyer-Hoffert U, Harder J. Decreased susceptibility of Staphylococcus aureus small-colony variants toward human antimicrobial peptides. J Invest Dermatol. 2014;134(9):2347-50. doi: 10.1038/jid.2014.176. [PubMed: 24717245].
  • 18. Firat YH, Simanski M, Rademacher F, Schroder L, Brasch J, Harder J. Infection of keratinocytes with Trichophytum rubrum induces epidermal growth factor-dependent RNase 7 and human beta-defensin-3 expression. PLoS One. 2014;9(4). e93941. doi: 10.1371/journal.pone.0093941. [PubMed: 24747887]. [PubMed Central: PMC3991580].
  • 19. Fritz P, Beck-Jendroschek V, Brasch J. Inhibition of dermatophytes by the antimicrobial peptides human beta-defensin-2, ribonuclease 7 and psoriasin. Med Mycol. 2012;50(6):579-84. doi: 10.3109/13693786.2012.660203. [PubMed: 22332906].
  • 20. Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol. 2003;30(3 Suppl 7):3-14. doi: 10.1016/S0093-7754(03)70010-4. [PubMed: 12840796].
  • 21. Burgess AW. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors. 2008;26(5):263-74. doi: 10.1080/08977190802312844. [PubMed: 18800267].
  • 22. Han W, Lo HW. Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012;318(2):124-34. doi: 10.1016/j.canlet.2012.01.011. [PubMed: 22261334]. [PubMed Central: PMC3304012].
  • 23. Eilers RE, Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47-53. doi: 10.1093/jnci/djp439. [PubMed: 20007525].
  • 24. Schroder JM. Antimicrobial peptides in healthy skin and atopic dermatitis. Allergol Int. 2011;60(1):17-24. doi: 10.2332/allergolint.10-RAI-0292. [PubMed: 21252615].
  • 25. Hutvagner G. Small RNA asymmetry in RNAi: Function in RISC assembly and gene regulation. FEBS Lett. 2005;579(26):5850-7. doi: 10.1016/j.febslet.2005.08.071. [PubMed: 16199039].
  • 26. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18(2):79-88. doi: 10.1016/j.semcancer.2008.01.002. [PubMed: 18291671].
  • 27. Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol. 2011;12(4):319-21. doi: 10.1016/S1470-2045(11)70067-5. [PubMed: 21463831].
  • 28. Li M, Li J, Ding X, He M, Cheng SY. MicroRNA and cancer. AAPS J. 2010;12(3):309-17. doi: 10.1208/s12248-010-9194-0. [PubMed: 20422339]. [PubMed Central: PMC2895440].
  • 29. McManus MT. MicroRNAs and cancer. Semin Cancer Biol. 2003;13(4):253-8. [PubMed: 14563119].
  • 30. Montano M. MicroRNAs: MiRRORS of health and disease. Transl Res. 2011;157(4):157-62. doi: 10.1016/j.trsl.2011.02.001. [PubMed: 21420026]. [PubMed Central: PMC3073773].
  • 31. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer--new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21(3):470-9. doi: 10.1016/j.ceb.2009.03.002. [PubMed: 19411171].
  • 32. Wouters MD, van Gent DC, Hoeijmakers JH, Pothof J. MicroRNAs, the DNA damage response and cancer. Mutat Res. 2011;717(1-2):54-66. doi: 10.1016/j.mrfmmm.2011.03.012. [PubMed: 21477600].
  • 33. Wiemer EA. The role of microRNAs in cancer: No small matter. Eur J Cancer. 2007;43(10):1529-44. doi: 10.1016/j.ejca.2007.04.002. [PubMed: 17531469].
  • 34. McDaneld TG. MicroRNA: Mechanism of gene regulation and application to livestock. J Anim Sci. 2009;87(14 Suppl):E21-8. doi: 10.2527/jas.2008-1303. [PubMed: 18791136].
  • 35. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One. 2010;5(9). e12702. doi: 10.1371/journal.pone.0012702. [PubMed: 20856931]. [PubMed Central: PMC2938338].
  • 36. Piri F, Zarei Mahmoudabadi A, Ronagh A, Ahmadi B, Makimura K, Rezaei-Matehkolaei A. Assessment of a pan-dermatophyte nested-PCR compared with conventional methods for direct detection and identification of dermatophytosis agents in animals. Mycoses. 2018. doi: 10.1111/myc.12821. [PubMed: 29944743].
  • 37. Nishimura T, Nakamura K, Yamashita S, Ikeda S, Kigure K, Minegishi T. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. BMC Cancer. 2015;15:957. doi: 10.1186/s12885-015-1975-5. [PubMed: 26673416]. [PubMed Central: PMC4682234].
  • 38. Mohsenzadegan M, Fayazi MR, Abdolmaleki M, Bakhshayesh M, Seif F, Mousavizadeh K. Direct immunomodulatory influence of IFN-beta on human astrocytoma cells. Immunopharmacol Immunotoxicol. 2015;37(2):214-9. doi: 10.3109/08923973.2015.1014559. [PubMed: 25689952].
  • 39. Amir Y. [Medical mycology introduction to medical mycology superficial mycoses and saprophytic fungi]. 1. Tehran: Iran University of Medical Sciences; 2007. p. 36-44. Persian.
  • 40. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230-7. doi: 10.1200/JCO.2006.10.5437. [PubMed: 17664471].
  • 41. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-43. doi: 10.1126/science.1141478. [PubMed: 17463250].
  • 42. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005;11(22):8105-8. doi: 10.1158/1078-0432.CCR-05-0926. [PubMed: 16299242].
  • 43. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O'Brien C, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):12-7. doi: 10.1016/j.bbrc.2007.03.201. [PubMed: 17475218].
  • 44. Smijs TG, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on Trichophyton rubrum. Photochem Photobiol. 2011;87(1):2-13. doi: 10.1111/j.1751-1097.2010.00848.x. [PubMed: 21114670].
  • 45. Simanski M, Rademacher F, Schroder L, Schumacher HM, Glaser R, Harder J. IL-17A and IFN-gamma synergistically induce RNase 7 expression via STAT3 in primary keratinocytes. PLoS One. 2013;8(3). e59531. doi: 10.1371/journal.pone.0059531. [PubMed: 23555696]. [PubMed Central: PMC3605401].
  • 46. Chae H, Rhee S, Nephew KP, Kim S. BioVLAB-MMIA-NGS: MicroRNA-mRNA integrated analysis using high-throughput sequencing data. Bioinformatics. 2015;31(2):265-7. doi: 10.1093/bioinformatics/btu614. [PubMed: 25270639].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments